LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-19. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
1.7 L (1,686 cc) 4EE1-T, I4 8-valve SOHC, turbo-diesel, 82–88 PS (60–65 kW; 81–87 hp) / 167–168 N⋅m (123–124 lb⋅ft) (1995–1998) 2.0 L (1,998 cc) RF, I4 8-valve SOHC, 71 PS (52 kW; 70 hp) / 128 N⋅m (94 lb⋅ft) (1996–1999)
=== 1970s === 1975: Chien-Shiung Wu, born in China but having become an American citizen in 1954, became the first female president of the American Physical Society. 1976: Margaret Burbidge, born in England, was named as the first female president of the American Astronomical Society. 1977: Rosalyn Yalow received the Nobel Prize in Physiology or Medicine "for the development of radioimmunoassays of peptide hormones"; she shared it with Roger Guillemin and Andrew V. Schally "for their discoveries concerning the peptide hormone production of the brain." 1978: Anna Jane Harrison became the first female president of the American Chemical Society. 1978: Mildred Cohn served as the first female president of the American Society for Biochemistry and Molecular Biology, then called the American Society of Biological Chemists.
Increasing temperature, which evens out the Boltzmann population of states. Conversely, low temperature NMR can sometimes yield better results than room-temperature NMR, providing the sample remains liquid. Saturation of the sample with energy applied at the resonant radiofrequency. This manifests in both CW and pulsed NMR; in the first case (CW) this happens by using too much continuous power that keeps the upper spin levels completely populated; in the second case (pulsed), each pulse (that is at least a 90° pulse) leaves the sample saturated, and four to five times the (longitudinal) relaxation time (5T1) must pass before the next pulse or pulse sequence can be applied. For single pulse experiments, shorter RF pulses that tip the magnetization by less than 90° can be used, which loses some intensity of the signal, but allows for shorter recycle delays. The optimum there is called an Ernst angle, after the Nobel laureate. Especially in solid state NMR, or in samples containing very few nuclei with spin (diamond with the natural 1% of carbon-13 is especially troublesome here) the longitudinal relaxation times can be on the range of hours, while for proton-NMR they are often in the range of one second. Non-magnetic effects, such as electric-quadrupole coupling of spin-1 and spin-3/2 nuclei with their local environment, which broaden and weaken absorption peaks. 14N, an abundant spin-1 nucleus, is difficult to study for this reason. High-resolution NMR instead probes molecules using the rarer 15N isotope, which has spin-1/2.
=== As a drug target === Because the specific activity of STAT5a has not been extensively investigated, most potential therapeutic treatments aim to target STAT5a/b. So far, the only reported potential therapeutic benefit specific to STAT5a has been in colorectal cancer. Inhibition of STAT5a alone would not effect colorectal cancer cells, but when combined with chemotherapies such as cisplatin, it could increase the chemosensitivity of the cancer cells to the drugs. Therapy schemes currently focus on STAT5a/b, targeting and inhibiting different mediators of the JAK2-STAT5 pathway.
Daisho (Dso) is an antimicrobial peptide gene family of the fruit fly Drosophila melanogaster. Two Daisho genes (Dso1, Dso2) are encoded in tandem in the fruit fly genome, one shorter than the other. This pair of genes with different length was named "Daisho" in reference to Daisho Japanese swords, which come in pairs with one shorter than the other. The Daisho genes are regulated by Drosophila Toll-like receptor signalling. Daisho peptides protect flies against filamentous fungi, particularly Fusarium and also Aspergillus. Daisho peptides are part of the Drosophila antifungal effector peptide response, which includes the gene families Bomanin, Drosomycin, Metchnikowin, and Baramicin.
Sources: en.wikipedia.org
== History == Vitamin E was discovered in 1922 by Herbert McLean Evans and Katharine Scott Bishop, first identified as a certain unknown substance necessary for fertility. Specifically, female rats raised on a diet of pure fat, carbohydrate, protein, salt, vitamins A and B were healthy in all apparent aspects, but they cannot carry a pregnancy to term, because they always reabsorb the fetus. Fertility is restored by supplementing the diet with certain foods (such as lettuce). Thus it was determined that a certain "anti-sterility vitamine" was present in these foods. This was the basis of a classical method for bioassaying the bioactivity of the various forms of vitamin E: the rat fetal resorption bioassay. Evans and collaborators used this to measure the presence and equivalent concentrations of vitamin E in many substances. For example, they measured the presence, concentration, and rate of decay of vitamin E storage in various body parts by "cannibal experiments". Rats fed on a scheduled diet of vitamin E were sacrificed daily, and their tissues were fed to sterile rats raised on the vitamin E-free diet. This restored fertility. It was also established that vitamin E is transferred intrauterinely from mother to pup, because sacrificed newborn pups can restore fertility. Vitamin E was first isolated in a pure form by Evans and Gladys Anderson Emerson in 1935 at the University of California, Berkeley.
Robert John Shiach, Cattleman. For services to the Cattle Industry in Banffshire. William Shiel. For services to Tourism in Northumbria. Trevor Royston Shore, Instructor/Examiner, Dorset County Council Cycle Training Scheme. For services to Road Safety. Joan Silcox. For charitable services in Newcastle-upon-Tyne. Annie Mary Simpson. For services to Education. Sylvia Yvonne Simpson. For services to the Police. Jean Skinner, School Crossing Patrol Warden, Kent County Council. For services to Road Safety. Robert Skinner. For services to the St Andrew's Ambulance Association. David Slater. For services to the community in Worksop Nottinghamshire. Eileen Lorraine Smart, Administrative Assistant, Department of Trade and Industry. Gwenneth Maude Muriel Smewin, lately Headteacher, Dunmore County Infants School, Abingdon, Oxfordshire. For services to Education. Barbara Antoinette Smith, Senior Nurse Manager, Leicester General Hospital. For services to Health Care. Brenda Smith. For charitable services. Carol Beverley Smith, Motor Transport Driver, Ministry of Defence. Graham Arthur Smith, Engineering Manager, Secure Products, Siemens Plessey Systems Ltd. For services to Defence Technology. John McCrindle Smith, . For services to the Magistracy and to the Police Committee in Essex. The Reverend Canon John Reginald Smith. For services to the community in Bury, Greater Manchester. Pauline Smith. For services to the Citizens' Advice Bureau in Sale, Cheshire. Thomas Robert Smith. For services to the community in High Wycombe, Buckinghamshire. Stuart Alan Spears.
=== Lipid changes === Spironolactone has been found to increase LDL ("bad") cholesterol and decrease HDL ("good") cholesterol levels at the relatively high doses used in women with polycystic ovary syndrome. As such, it may have unfavorable effects on the blood lipid profile in this context. Heightened LDL cholesterol levels are a potential risk factor for cardiovascular disease, such as atherosclerosis or coronary heart disease. Consequently, spironolactone probably should not be given to women with dyslipidemia (e.g., high cholesterol). Unfavorable lipid changes have also been seen with other antiandrogens, such as cyproterone acetate and bicalutamide.
In bioinformatics and biochemistry, the FASTA format is a text-based format for representing either nucleotide sequences or amino acid (protein) sequences, in which nucleotides or amino acids are represented using single-letter codes. The format allows for sequence names and comments to precede the sequences. It originated from the FASTA software package and has since become a near-universal standard in bioinformatics. The simplicity of FASTA format makes it easy to manipulate and parse sequences using text-processing tools and scripting languages.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.